Mitogenic conversion of transforming growth factor-β1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3031-3038

  Park, Bum Joon ^a   Park, Jae Il ^a   Byun, Do Sun ^a   Park, Jae Hoon ^a   Chi, Sung Gil ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P15; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOGENESIS; ONCOGENE RAS; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

CELL CYCLE; CELL DIVISION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; FLOW CYTOMETRY; GENES, RAS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; ONCOGENE PROTEIN P21(RAS); POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0034214211     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Massague, J. The transforming growth factor-β family. Annu. Rev. Cell Biol., 6: 597-641, 1990.
2. Heldin, C. H., Miyazono, K., and ten Dijke, P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond.), 390: 465-471, 1997.
3. Markowitz, S., Wang, J., Meyeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B. Brattain, M., and Wilson, J. K. V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
4. Kim, I. Y., Ahn. H-J., Zelner, D. J., Shaw, J. W., Sensibar, J. A., Kim, J-H., Kato, M., and Lee, C. Genetic change in transforming growth factor β(TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res., 56: 44-48, 1996.
5. Ito, N., Kawata, S., Tamora, S., Takaishi, K., Shirai, Y., Kiso, S., Yabeurchi, I., Matsuda, Y., Nishioka, M., and Tarui, S. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res., 51: 4080-4083, 1991.
6. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of mRNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707-712, 1987.
7. Yang, E. Y., and Moses, H. L. Transforming growth factor-β1 induces changes on cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol., 111: 731-741, 1990.
8. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., and Lowley, D. A. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 87: 1486-1490, 1990.
9. Wilding, G., Zugmeier, G., Knabbe, C., Flanders, K., and Gelmann, E. Differential effects of transforming growth factor TGF-β on human prostate cell in vitro. Mol. Cell. Endocrinol., 62: 79-87, 1989.
10. Williams, R. H., Stapleton, A. M. F., Yang, G., Truong, L. D., Rogers, E., Timme, T. L., Wheeler, T. M., Scardino, P. T., and Thompson, T., C. Reduced levels of transforming growth factor β receptor type II in human prostate cancer: an immunohistochemical study. Clin. Cancer Res., 2: 635-640, 1996.
11. Kim, I. Y., Ahn, H-J., Lang, S., Oefelein, M. G., Oyasu, R., Kozlowski, J. M., and Lee, C. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res., 4: 1625-1630, 1998.
12. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Thompson, T. C. Association of transforming growth factor type-β1 with prostate cancer: an immunohistochemical study. Hum. Pathol., 24: 4-9, 1993.
13. Eastham, J. A., Truong, L. D., Rogers, E., Kattan, M., Flanders, K. C., Scardino, P. T., and Thompson, T. C. Transforming growth factor-β1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab. Investig., 73: 628-635, 1995.
14. Sehgal, I., Baley, P. A., Thompson, T. C. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-driven cell lines in vitro. Cancer Res., 56: 3359-3365, 1996.
15. Barrack, E. R. TGF-β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31: 61-70, 1997.
16. Stearns, M. E., Garcia, F. U., Fudge, K., Rhim, J., and Wang, M. Role of interleukin 10 and transforming growth factor-β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin. Cancer Res., 5: 711-720, 1999.
17. Bos, J. L. Ras oncogenes in human cancer, a review. Cancer Res., 49: 4682-4689, 1989.
18. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
19. Kretzschmar, M., Doody, J., Timokhina, L. and Massague, J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev., 13: 804-816, 1999.
20. Schwarz, L. C., Gingras, M. C., Goldberg, G., Greenberg, A. H., and Wright, J. A. Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res., 48: 6999-7003, 1988.
21. 1 growth arrest by transforming growth factor-β1 requires ras activity. J. Biol. Chem., 268: 21448-21452, 1993.
22. Oft, M., Peli, J., Rudaz. C., Schwarz, H., Beug, H., Reichmann, E. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev., 10: 2462-2477, 1996.
23. Carter, B. S., Epstein, J. I., and Issacs, W. B. ras gene mutations in human prostate cancer. Cancer Res., 50: 6830-6832, 1990.
24. Gumerlock, P. H., Poonamallee, U. R., Meyers, F. J., and deVere White, R. W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res., 51: 1632-1637, 1991.
25. Watanabe, M., Shiraishi, T., Yatani, R., Nomura, A. M., and Stemmermann, G. N. International comparison on ras gene mutations in latent prostate carcinoma. Int. J. Cancer. 58: 174-178, 1994.
26. Bushman, E. C., Nayak, R. N., and Bushman, W. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue. J. Urol., 153: 233-237, 1995.
27. Agnantis, N. J., Constantinidou, A. E., Papaevagelou, M., and Apostolikas, N. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res., 14: 2135-2140, 1994.
28. INK4A/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res., 3: 1889-1897, 1997.
29. Tricoli, J. V., Gumerlock, P. H., Yao, J. L., Chi, S-G., D'Souza, S. A., Nestok, B. R., deVere White, R. W., and The Cooperative Prostate Network, National Cancer Institute. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer, 15: 108-114, 1996.
30. Lamm, M. L. G., Sintich, S. M., and Lee, C. A proliferate effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology, 139: 787-790, 1998.
31. Sintich, S. M., Lamm, M. L., Sensibar, J. A., and Lee, C. Transforming growth factor-β1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor. Endocrinology, 140: 3411-3415, 1999.
32. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
33. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
34. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
35. ras by transforming growth factor β in epithelial cells. J. Biol. Chem., 267: 5029-5031, 1992.
36. Oft, M., Heinz, K-H., and Beug, H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol., 8: 1243-1252, 1998.
37. Stolz, D. B., and Michalopoulos, G. K. Synergistic enhancement of EGF, but not HGF, stimulated hepatocyte mobility by TGF-β1 in vitro. J. Cell Physiol., 170: 57-68, 1997.
38. de Caestecker, M. P., Parks, W. T., Frank, C. J., Castagnino, P., Bottaro, D. P., Roberts, A. B., and Lechleider, R. J. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev., 12: 1587-1592, 1998.
39. Merz, V. W., Miller, G. J., Krebs, T., Timme, T. L., Kadmon, D., Park, S. H., Egawa, S., Scardino, P. T., and Thompson, T. C. Elevated transforming growth factor-β1 and β3 levels are associated with ras+myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol. Endocrinol., 5: 503-513, 1991.
40. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
41. Yeh, S., Lin, H-K., Kang, H-Y., Thin, T. H., Lin, M-F., and Chang, C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 96: 5458-5463, 1999.
42. Sikes, R. A., and Chung, L. W. K. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res., 52: 3174-3181, 1992.
43. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst., 86: 1140-1145, 1994.
44. Qiu, Y., Ravi, L., and Kung, H-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (Lond.), 393: 83-85, 1998.
45. INK4B through an Sp1 consensus site. J. Biol. Chem., 270: 26750-26753, 1995.
46. Moustakas, A., and Kardassis, D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA, 95: 6733-6738, 1998.
47. Waf1 expression and growth inhibilion by transforming growth factor-β involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res., 57: 3929-3934, 1997.
48. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev., 11: 492-503, 1997.
49. Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M., and Massague, J. Growth inhibition by TGF-β1 linked to suppression of retinoblastoma protein phosphorylation. Cell, 62: 175-185, 1990.
50. Miyazaki, M., Ohashi, R., Tsuji, T., Mihara, K., Gohda, E., and Namba, M. Transforming growth factor-β1 stimulates or inhibits cell growth via down-or up-regulation of p21/Waf1. Biochem. Biophys. Res. Commun., 246: 873-880, 1998.
51. Olson, M. F., Paterson, H. F., and Marshall, C. J. Signals from Ras and Rho GTPase interact to regulate expression of p21Waf1/Cip1. Nature (Lond.), 394: 295-299, 1998.
52. Atfi, A., Djelloul, S., Chastre, E., Davis, R., and Gespach, C. Evidence for a role of Rho-like GTPase and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor-β-mediated signaling. J. Biol. Chem., 272: 1429-1432, 1997.